Literature DB >> 3347742

Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody.

J A Carrasquillo1, P Sugarbaker, D Colcher, J C Reynolds, J Esteban, G Bryant, P Perentesis, K Yokoyama, M Rotman, J Schlom.   

Abstract

Monoclonal antibody (MoAb) B72.3 is reactive with a variety of carcinomas such as colorectal and ovarian carcinoma and not reactive with a range of normal tissues in adults. Twelve patients, ranging in age from 16 to 63 years, with metastatic colorectal or appendiceal carcinoma were studied by means of radioimmunoscintigraphy after injection of 5-10 mCi (185-370 MBq) of iodine-131-labeled B72.3 immunoglobulin G (IgG). Eight of the 12 patients had positive scans. In three of these patients the MoAb scan depicted tumors that were not found by other means. Positive scans had excellent correlation with surgical findings in seven patients and caused underestimation of the extent of disease in one patient. In one patient the scan was technically inadequate and could not be evaluated. In three patients the scan was negative. No adverse reactions were associated with the infusions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3347742     DOI: 10.1148/radiology.167.1.3347742

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

Review 1.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study.

Authors:  R J Doerr; H Abdel-Nabi; D Krag; E Mitchell
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

Review 3.  Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions.

Authors:  R M Reilly; J Sandhu; T M Alvarez-Diez; S Gallinger; J Kirsh; H Stern
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

4.  Radioimmunotherapy for pancreatic carcinoma using (131)I-labeled monoclonal antibody Nd2 in xenografted nude mice.

Authors:  A Inui; Y S Chung; T Sawada; Y Kondo; J J Ho; Y S Kim; M Sowa
Journal:  Jpn J Cancer Res       Date:  1996-09

5.  Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.

Authors:  Y S Chung; T Sawada; Y Kondo; K Hirayama; A Inui; Y Yamashita; B Nakata; T Okamura; H Ochi; J J Ho; Y S Kim; M Sowa
Journal:  Jpn J Cancer Res       Date:  1997-04

6.  Detection of peritoneal metastases.

Authors:  J C Healy
Journal:  Cancer Imaging       Date:  2001-02-01       Impact factor: 3.909

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.